BWXT Medical and NorthStar Partner to Produce Cancer-Fighting Isotope Ac-225

BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE:BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.

Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. Pursuant to the multi-year MSA, the companies will work together to process and purify radium-226. The scope of the agreement also includes potential target design projects and exploration of opportunities to provide backup supply to each other's customers.